Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Hims & Hers Health, Inc. (HIMS) has garnered significant investor attention, yet its shares have declined 14.8% over the past month, underperforming the S&P 500's 5.2% gain. Despite this recent stock weakness, the company projects robust financial performance, with current quarter EPS estimated to rise 183.3% year-over-year to $0.17 and sales expected to grow 74.8% to $551.84 million. HIMS also recently reported a substantial 110.7% year-over-year revenue increase and an EPS of $0.2 last quarter, beating consensus estimates. However, the stock holds a Zacks Rank #3 (Hold), indicating a potential near-term performance in line with the broader market, despite its strong growth projections.

Analysis

Hims & Hers Health, Inc. (HIMS) presents a notable divergence between its recent market performance and its underlying fundamental growth metrics. The stock has significantly underperformed, declining 14.8% over the past month in stark contrast to the S&P 500's 5.2% gain. Despite this price weakness, the company's operational growth is robust. It recently reported a 110.7% year-over-year revenue increase to $586.01 million and an EPS of $0.2, representing substantial surprises of +8.9% and +66.67% over consensus estimates, respectively. Looking ahead, analyst consensus projects this powerful growth to continue, with current quarter revenue expected to rise 74.8% and EPS to surge 183.3%. However, this bullish outlook is tempered by a few factors: the consensus EPS estimate for the current fiscal year has been revised down slightly by 0.8% over the last 30 days, its valuation is considered at par with peers according to its Zacks Value Style Score of 'C', and it holds a Zacks Rank of #3 (Hold), suggesting it may only perform in line with the broader market in the near term.

Key Decisions for Investors

• Investors with a long-term growth thesis may see the recent 14.8% stock price decline as a potential entry point, given the company's powerful forward-looking revenue and earnings growth projections.
• Given the stock's significant recent underperformance and its Zacks Rank #3 (Hold), near-term focused investors should be cautious, as current market sentiment appears disconnected from the strong fundamentals.
• Closely monitor the next earnings report to validate if the company can maintain its exceptional growth trajectory and beat estimates, as continued operational outperformance may be required to reverse the negative stock momentum.
• Since the stock is trading at par with its peers and is not considered a value play, the investment case hinges on the company's ability to sustain its high-growth narrative.